The clinical characteristics and prognostic factors of 410 patients with natural killer/T-cell lymphoma

Purpose To investigate the clinical characteristics and prognostic factors of natural killer/T-cell lymphoma (NKTCL). Methods We retrospectively reviewed 410 NKTCL patients admitted to our lymphoma center from 2000 to 2019. Overall survival (OS) and progression-free survival (PFS) were estimated wit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cancer research and clinical oncology 2022-12, Vol.148 (12), p.3449-3459
Hauptverfasser: Sun, Zhenchang, Wan, Wenjuan, Zhang, Xudong, Zhang, Lei, Li, Xin, Li, Ling, Wang, Xinhua, Nan, Feifei, Yu, Hui, Chang, Yu, Yan, Jiaqin, Li, Zhaoming, Cui, Fangfang, Ge, Jurui, XiaXu, Yaqin Duo, Xu, Xia, Fu, Xiaorui, Zhang, Mingzhi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Purpose To investigate the clinical characteristics and prognostic factors of natural killer/T-cell lymphoma (NKTCL). Methods We retrospectively reviewed 410 NKTCL patients admitted to our lymphoma center from 2000 to 2019. Overall survival (OS) and progression-free survival (PFS) were estimated with the Kaplan–Meier method, and the differences between the study groups were compared by the log-rank test. Results The median age of the 410 patients was 44 (range 8–84), and the 5-year OS and PFS were 61.2% and 38.4%, respectively. For patients with stage I/II, the 5-year PFS rate was 57.5%, and the 5-year OS rate was 77.2%. For patients with stage III/IV, the 5-year PFS rate was 17.4%, and the 5-year OS rate was 43.7%. Compared to the patients who received radiotherapy alone or chemotherapy alone as their initial treatment, the patients who received combined chemoradiotherapy had longer PFS ( P  = 0.013). Independent prognostic factors for OS were stage III/IV ( P  = 0.001), elevated IPI/aaIPI score ( P  = 0.019), elevated PINK score ( P  
ISSN:0171-5216
1432-1335
DOI:10.1007/s00432-022-04203-x